Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.



This is a "connection" page, showing publications co-authored by Peter Anderson and Kristina Brooks.

Connection Strength
  1. Brooks KM, Ibrahim ME, Castillo-Mancilla JR, MaWhinney S, Alexander K, Tilden S, Kerr BJ, Ellison L, McHugh C, Bushman LR, Kiser JJ, Hosek S, Huhn GD, Anderson PL. Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. J Antimicrob Chemother. 2019 08 01; 74(8):2352-2359.
    View in: PubMed
    Score: 0.850
  2. Brooks KM, Anderson PL. Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention. Clin Pharmacol Ther. 2018 12; 104(6):1056-1059.
    View in: PubMed
    Score: 0.798
  3. Yager JL, Brooks KM, Castillo-Mancilla JR, Nemkov C, Morrow M, Peterson S, Ibrahim M, Bushman L, Kiser JJ, Mawhinney S, Anderson PL. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium, and high adherence to F/TAF vs. F/TDF. AIDS. 2021 Sep 02.
    View in: PubMed
    Score: 0.246
  4. Ibrahim ME, Castillo-Mancilla JR, Yager J, Brooks KM, Bushman L, Saba L, Kiser JJ, MaWhinney S, Anderson PL. Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis. AIDS Res Hum Retroviruses. 2021 06; 37(6):421-428.
    View in: PubMed
    Score: 0.234
  5. Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Rowan SE, Wyles D, Blum J, Huntley R, Salah LM, Tehrani A, Bushman LR, Anderson PL, Kiser JJ. Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. Open Forum Infect Dis. 2021 Jan; 8(1):ofaa564.
    View in: PubMed
    Score: 0.233
  6. Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Blum J, Wyles DL, Rowan SE, Ibrahim ME, Zheng JH, Johnson B, Gomez J, Choi YJ, Cendali F, Haas H, Roon L, Bushman LR, Anderson PL, Kiser JJ. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. J Antimicrob Chemother. 2020 11 01; 75(11):3303-3310.
    View in: PubMed
    Score: 0.232
  7. Yager J, Castillo-Mancilla J, Ibrahim ME, Brooks KM, McHugh C, Morrow M, McCallister S, Bushman LR, MaWhinney S, Kiser JJ, Anderson PL. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. J Acquir Immune Defic Syndr. 2020 07 01; 84(3):323-330.
    View in: PubMed
    Score: 0.227
  8. Brooks KM, Castillo-Mancilla JR, Blum J, Huntley R, MaWhinney S, Alexander K, Kerr BJ, Ellison L, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. J Antimicrob Chemother. 2019 08 01; 74(8):2360-2364.
    View in: PubMed
    Score: 0.213
  9. Ibrahim ME, Brooks KM, Castillo-Mancilla JR, McHugh C, Morrow M, Brothers J, MaWhinney S, Hosek S, Huhn G, Anderson PL. Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor. AIDS Res Hum Retroviruses. 2018 10; 34(10):835-837.
    View in: PubMed
    Score: 0.200
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)